Clinical Trial Update: Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease [Phase 1]

View source ↗

Summary

This is a Phase 1 safety study update for CAT-8015 immunotoxin in patients with hairy cell leukemia with advanced disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia
• Leukemia

Drugs mentioned

• CAT-8015 immunotoxin (CAT-8015)

Snippet

Sponsor: Cambridge Antibody Technology | Conditions: Leukemia, Hairy Cell Leukemia | Phase 1 | Status: UNKNOWN